FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2787145330> ?p ?o ?g. }

• W2787145330 endingPage "1531" @default.
• W2787145330 startingPage "1522" @default.
• W2787145330 abstract "Abstract Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase–polymerase chain reaction or flow cytometry. MRD is the strongest predictor of relapse in ALL. In this open-label, single-arm study, adults with B-cell precursor ALL in hematologic complete remission with MRD (≥10−3) received blinatumomab 15 µg/m2 per day by continuous IV infusion for up to 4 cycles. Patients could undergo allogeneic hematopoietic stem-cell transplantation any time after cycle 1. The primary end point was complete MRD response status after 1 cycle of blinatumomab. One hundred sixteen patients received blinatumomab. Eighty-eight (78%) of 113 evaluable patients achieved a complete MRD response. In the subgroup of 110 patients with Ph-negative ALL in hematologic remission, the Kaplan-Meier estimate of relapse-free survival (RFS) at 18 months was 54%. Median overall survival (OS) was 36.5 months. In landmark analyses, complete MRD responders had longer RFS (23.6 vs 5.7 months; P = .002) and OS (38.9 vs 12.5 months; P = .002) compared with MRD nonresponders. Adverse events were consistent with previous studies of blinatumomab. Twelve (10%) and 3 patients (3%) had grade 3 or 4 neurologic events, respectively. Four patients (3%) had cytokine release syndrome grade 1, n = 2; grade 3, n = 2), all during cycle 1. After treatment with blinatumomab in a population of patients with MRD-positive B-cell precursor ALL, a majority achieved a complete MRD response, which was associated with significantly longer RFS and OS compared with MRD nonresponders. This study is registered at www.clinicaltrials.gov as #NCT01207388." @default.
• W2787145330 created "2018-02-23" @default.
• W2787145330 creator A5000436961 @default.
• W2787145330 creator A5016275445 @default.
• W2787145330 creator A5018514641 @default.
• W2787145330 creator A5024202047 @default.
• W2787145330 creator A5026967725 @default.
• W2787145330 creator A5028673634 @default.
• W2787145330 creator A5029898558 @default.
• W2787145330 creator A5041945240 @default.
• W2787145330 creator A5047060286 @default.
• W2787145330 creator A5048490856 @default.
• W2787145330 creator A5058424325 @default.
• W2787145330 creator A5067228089 @default.
• W2787145330 creator A5067318724 @default.
• W2787145330 creator A5070044155 @default.
• W2787145330 creator A5072568698 @default.
• W2787145330 creator A5075073484 @default.
• W2787145330 creator A5077099095 @default.
• W2787145330 creator A5091739351 @default.
• W2787145330 date "2018-04-05" @default.
• W2787145330 modified "2023-10-18" @default.
• W2787145330 title "Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia" @default.
• W2787145330 cites W1485389706 @default.
• W2787145330 cites W1967348190 @default.
• W2787145330 cites W1976270016 @default.
• W2787145330 cites W1981648274 @default.
• W2787145330 cites W1987538151 @default.
• W2787145330 cites W1989658067 @default.
• W2787145330 cites W1991184842 @default.
• W2787145330 cites W1991644988 @default.
• W2787145330 cites W1998660089 @default.
• W2787145330 cites W2007234423 @default.
• W2787145330 cites W2035343180 @default.
• W2787145330 cites W2038414910 @default.
• W2787145330 cites W2039642633 @default.
• W2787145330 cites W2045459197 @default.
• W2787145330 cites W2049000194 @default.
• W2787145330 cites W2050152294 @default.
• W2787145330 cites W2058885398 @default.
• W2787145330 cites W2069085828 @default.
• W2787145330 cites W2075101185 @default.
• W2787145330 cites W2075139424 @default.
• W2787145330 cites W2081127271 @default.
• W2787145330 cites W2085656861 @default.
• W2787145330 cites W2099570622 @default.
• W2787145330 cites W2107925822 @default.
• W2787145330 cites W2109388187 @default.
• W2787145330 cites W2118241155 @default.
• W2787145330 cites W2118796952 @default.
• W2787145330 cites W2151069914 @default.
• W2787145330 cites W2161996216 @default.
• W2787145330 cites W2346714313 @default.
• W2787145330 cites W2588300170 @default.
• W2787145330 cites W2591709377 @default.
• W2787145330 cites W2613210669 @default.
• W2787145330 doi "https://doi.org/10.1182/blood-2017-08-798322" @default.
• W2787145330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6027091" @default.
• W2787145330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29358182" @default.
• W2787145330 hasPublicationYear "2018" @default.
• W2787145330 type Work @default.
• W2787145330 sameAs 2787145330 @default.
• W2787145330 citedByCount "519" @default.
• W2787145330 countsByYear W27871453302018 @default.
• W2787145330 countsByYear W27871453302019 @default.
• W2787145330 countsByYear W27871453302020 @default.
• W2787145330 countsByYear W27871453302021 @default.
• W2787145330 countsByYear W27871453302022 @default.
• W2787145330 countsByYear W27871453302023 @default.
• W2787145330 crossrefType "journal-article" @default.
• W2787145330 hasAuthorship W2787145330A5000436961 @default.
• W2787145330 hasAuthorship W2787145330A5016275445 @default.
• W2787145330 hasAuthorship W2787145330A5018514641 @default.
• W2787145330 hasAuthorship W2787145330A5024202047 @default.
• W2787145330 hasAuthorship W2787145330A5026967725 @default.
• W2787145330 hasAuthorship W2787145330A5028673634 @default.
• W2787145330 hasAuthorship W2787145330A5029898558 @default.
• W2787145330 hasAuthorship W2787145330A5041945240 @default.
• W2787145330 hasAuthorship W2787145330A5047060286 @default.
• W2787145330 hasAuthorship W2787145330A5048490856 @default.
• W2787145330 hasAuthorship W2787145330A5058424325 @default.
• W2787145330 hasAuthorship W2787145330A5067228089 @default.
• W2787145330 hasAuthorship W2787145330A5067318724 @default.
• W2787145330 hasAuthorship W2787145330A5070044155 @default.
• W2787145330 hasAuthorship W2787145330A5072568698 @default.
• W2787145330 hasAuthorship W2787145330A5075073484 @default.
• W2787145330 hasAuthorship W2787145330A5077099095 @default.
• W2787145330 hasAuthorship W2787145330A5091739351 @default.
• W2787145330 hasBestOaLocation W27871453301 @default.
• W2787145330 hasConcept C121608353 @default.
• W2787145330 hasConcept C126322002 @default.
• W2787145330 hasConcept C143998085 @default.
• W2787145330 hasConcept C203014093 @default.
• W2787145330 hasConcept C2777408962 @default.
• W2787145330 hasConcept C2777701055 @default.
• W2787145330 hasConcept C2778020697 @default.
• W2787145330 hasConcept C2778461978 @default.
• W2787145330 hasConcept C2779823535 @default.

• next